Showing 1431-1440 of 5771 results for "".
- LENZ Therapeutics and Graphite Bio Announce Mergerhttps://modernod.com/news/lenz-therapeutics-and-graphite-bio-announce-merger/2481971/LENZ Therapeutics and Graphite Bio announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia. The combined company is expected to trade on Nasdaq under the t
- EyeBio Announces Expansion of Series A to $130 Million to Advance Development of Restoret for Retinal Diseaseshttps://modernod.com/news/eyebio-announces-expansion-of-series-a-to-130-million-to-advance-development-of-restoret-for-retinal-diseases/2481969/Eyebiotech announced the successful close of an extension to its Series A financing, bringing the total raised to date to $130 million. EyeBio will use the proceeds from the funding to accelerate the company’s clinical development program and further build out its retina pipeline.
- Pixium Vision Announces 48-Month Trial Results in Severe Atrophic AMDhttps://modernod.com/news/pixium-vision-announces-48-month-trial-results-in-severe-atrophic-amd/2481963/Pixium Vision SA announced data from a first in human trial to assess the efficacy and safety of the PRIMA photovoltaic retinal stimulation microchip for improving visual acuity (VA) 48 months post implantation in patients with severe central vision impairment due to dry age-related mac
- Visionix Announces Strategic Partnership with 20/20NOWhttps://modernod.com/news/visionix-announces-strategic-partnership-with-2020now/2481957/Visionix USA announced it has entered a into a strategic alliance with 20/20NOW with the aim of bringing cost-effective, in-office, synchronous tele-optometry eye exams and ocular telemedicine closer to more patients throughout the United States. Financial terms of the deal we
- Bausch + Lomb Announces Publication of Miebo Phase 3 Extension Trial Datahttps://modernod.com/news/bausch-lomb-announces-publication-of-miebo-phase-3-extension-trial-data/2481953/Bausch + Lomb announced that Cornea has
- Ocuphire Pharma Announces End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathyhttps://modernod.com/news/ocuphire-pharma-announces-end-of-phase-2-meeting-with-fda-for-oral-apx3330-in-diabetic-retinopathy/2481935/Ocuphire Pharma announced the successful outcome of an end-of-phase 2 (EOP2) meeting with the FDA supporting the advancement of oral APX3330 for the treatment of diabetic retinopathy (DR) into phase 3 studies based on the recently completed phase 2 ZETA-1 trial. “We are
- AffaMed Therapeutics Announces Positive Topline Results from Real-World Study in China Evaluating Dextenza in Patients after Cataract Surgeryhttps://modernod.com/news/affamed-therapeutics-announces-positive-topline-results-from-real-world-study-in-china-evaluating-dextenza-in-patients-after-cataract-surgery/2481932/AffaMed Therapeutics announced positive topline results from the real-world study conducted in the Boao Lecheng Pilot Zone in Hainan, China, to evaluate the safety and efficacy of Dextenza (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain followi
- Centricity Vision Announces Commercial Launch of ZEPTOLink IOL Positioning System at AAOhttps://modernod.com/news/centricity-vision-announces-commercial-launch-of-zeptolink-iol-positioning-system-at-aao/2481931/Centricity Vision announced the commercial launch of its ZEPTOLink IOL Positioning System at the American Academy of Ophthalmology (AAO) annual meeting, November 3-6 in San Francisco. The new platform integrates the ZEPTO precision pulse capsulotomy technology with any phaco s
- Ocuphire Pharma Announces Appointment of George Magrath, MD, MS, as Chief Executive Officer and Directorhttps://modernod.com/news/ocuphire-pharma-announces-appointment-of-george-magrath-md-ms-as-chief-executive-officer-and-director/2481927/Ocuphire Pharma announced the appointment of George Magrath, MD, MS, as Chief Executive Officer and member of the Board of Directors, effective today. Dr. Magrath succeeds Rick Rodgers, Interim CEO and President since April 2023. Mr. Rodgers will remain on the company’s Board of Direct
- Opthea Announces Changes to Executive Leadershiphttps://modernod.com/news/opthea-appoints-us-based-leadership-with-fred-guerard-as-ceo-and-peter-lang-as-cfo/2481918/Opthea announced that the company’s Chief Executive Officer, Megan Baldwin, PhD, will transition to Founder and Chief Innovation Officer, effective today. The company says the move is reflective of the company’s strategy to advance its US and global presence and commercialization